Compare General Mills, Inc. (GIS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Moderna, Inc. — how do they compare? General Mills, Inc. trades at $38.71 (market cap $19.46B), while Moderna, Inc. trades at $62.97 (market cap $27.09B). The key difference: Moderna, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.69% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GIS | MRNA | |
|---|---|---|
Market Cap | $19.46B | $27.09B |
Sector | Consumer Staples | Health |
52-Week High | $51.27 | $81.80 |
52-Week Low | $32.17 | $22.36 |
Enterprise Value | $32.95B | $23.19B |
Dividend Yield | 6.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $38.95, up 6.83% in the last session, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue declined to $19.49B in 2025, with net income margin turning negative at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to support margins amid soft demand.
The outlook is cautious; while valuation appears attractive with a P/E of 9.23, weak sales and profit pressure pose risks. Analyst consensus is mixed with 22.22% buy ratings, but the average price target of $36.14 suggests limited upside. Key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
